# A Study of CPI-613 for Patients With Relapsed or Refractory Burkitt Lymphoma/Leukemia or High-Grade B-Cell Lymphoma With High-Risk Translocations

> **NCT03793140** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 24 (estimated)

## Conditions studied

- Lymphoma
- Leukemia

## Interventions

- **DRUG:** CPI-613

## Key facts

- **NCT ID:** NCT03793140
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2018-12-31
- **Primary completion:** 2026-12
- **Final completion:** 2026-12
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2026-03-27

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03793140

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03793140, "A Study of CPI-613 for Patients With Relapsed or Refractory Burkitt Lymphoma/Leukemia or High-Grade B-Cell Lymphoma With High-Risk Translocations". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT03793140. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*